Environmental scan of anal cancer screening practices: worldwide survey results

Jigisha Patel, Irving E. Salit, Michael J. Berry, Alexandra de Pokomandy, Mayura Nathan, Fred Fishman, Joel Palefsky & Jill Tinmouth

1Sunnybrook Health Sciences Centre, Toronto, Canada
2University of Toronto, Toronto, Canada
3Toronto General Hospital, Toronto, Canada
4University of California, San Francisco, California
5McGill University, Montreal, Canada
6Homerton University Hospital, London, United Kingdom

Abstract

Anal squamous cell carcinoma is rare in the general population but certain populations, such as persons with HIV, are at increased risk. High-risk populations can be screened for anal cancer using strategies similar to those used for cervical cancer. However, little is known about the use of such screening practices across jurisdictions. Data were collected using an online survey. Health care professionals currently providing anal cancer screening services were invited to complete the survey via email and/or fax. Information was collected on populations screened, services and treatments offered, and personnel. Over 300 invitations were sent; 82 providers from 80 clinics around the world completed the survey. Fourteen clinics have each examined more than 1000 patients. Over a third of clinics do not restrict access to screening; in the rest, eligibility is most commonly based on HIV status and abnormal anal cytology results. Fifty-three percent of clinics require abnormal anal cytology prior to performing high-resolution anoscopy (HRA) in asymptomatic patients. Almost all clinics offer both anal cytology and HRA. Internal high-grade anal intraepithelial neoplasia (AIN) is most often treated with infrared coagulation (61%), whereas external high-grade AIN is most commonly treated with imiquimod (49%). Most procedures are performed by physicians, followed by nurse practitioners. Our study is the first description of global anal cancer screening practices. Our findings may be used to inform practice and health policy in jurisdictions considering anal cancer screening.

Background

Anal squamous cell carcinoma is rare in the general population, but its incidence is rising [1–3]. In the United States, incidence rates are ~1.24 per 100,000 person-years in men and 1.47 per 100,000 person-years in women [4]. Rates of anal cancer are particularly elevated in HIV-infected men who have sex with men (MSM) and in other immunosuppressed persons such as transplantation recipients [2, 5–8]. In a systematic review the pooled incidence was reported as 46 per 100,000 person-years in HIV-infected MSM in nine studies conducted in the pre and post highly active antiretroviral therapy (HAART) eras [9]. Prolonged survival due to the introduction of HAART appears to increase the risk of developing anal cancer in HIV-infected men [2]. The impact of the HIV epidemic has significantly increased anal cancer incidence in men [3] perhaps partially accounting for the high incidence (131 per 100,000 person-years) reported in a recent North American cohort study [8]. Currently, rates of anal cancer in HIV-infected MSM are higher than cervical cancer reported anywhere in the world [10]. Anal cancer and cervical cancer are biologically very similar; both are caused by persistent infection with
high-risk types of human papillomavirus (HPV) leading to cellular oncogenic transformation at squamo-columnar junctions [11, 12]. In HIV-infected patients and in MSM, the prevalence of any anal HPV infection is particularly high (86–98%) [11, 13–17]; these patients have an increased risk of anal intraepithelial neoplasia (AIN), the precursor to anal cancer [18–20]. Up to 92% of anal cancers are associated with oncogenic HPV [21–23]. Because the cancers are so analogous, cervical cancer screening strategies have been applied to anal cancer. Anal cytology (also referred to as the “anal Pap smear”) and high-resolution anoscopy (HRA), which is similar to colposcopy, have been used to facilitate the detection of AIN and early invasive cancer in published literature [24]. Because of the widely recognized benefits of screening for cervical cancer, there is considerable enthusiasm for anal cancer screening in high-risk populations such as HIV-infected MSM, however, little is known about current implementation of such screening practices across jurisdictions.

The objective of this study was to characterize anal cancer screening practices in jurisdictions around the world with the aims of providing clinical and operational guidance for clinicians, describing the current practice and providing information from other jurisdictions for health care policy makers.

Methods

Clinicians and scientists currently providing anal cancer screening were invited to complete an Internet-based survey. We used a variety of strategies to contact participants from around the world. Potential respondents were identified from a review of the published literature, conference abstract books, and list of physicians who had been trained in HRA provided by the American Society for Colposcopy and Cervical Pathology (ASCCP). To our knowledge, the ASCCP is the only organization that provides formal training in HRA in the world. As such, our recruitment strategy should have identified a high percentage of clinicians who are practicing in this field.

Participants were invited to complete the survey via email and/or fax in April 2011. Survey questions were deployed using a web-based survey tool (Survey Monkey™, Palo Alto, CA). Participants were asked to answer up to 40 questions about their practice and their clinic or program. Information was collected on populations screened, services and treatments offered, and personnel. Respondent data were exported from Survey Monkey and descriptive analyses (counts, percentages/proportions) were performed.

Results

Over 300 email/fax invitations were sent; 82 providers from 80 clinics in Canada, USA, Europe, Asia, and Australia completed the survey.

Clinic/program

Most clinics are relatively new and consequently, have only provided care to a small volume of patients. While 34 (43%) clinics have examined fewer than 100 patients, 14 (18%) clinics have examined more than 1000 patients since their inception (Table 1). Almost all clinics offer anal cytology (98%) and HRA (99%). Treatment of high-grade (89%) and low-grade (84%) AIN is also offered in most clinics, however, just 59% of the clinics offer HPV testing using either PCR, hybrid capture, or both. Physicians, followed by nurse practitioners, most commonly performed the procedures (Table 2). Approximately 1/3 of clinics do not risk stratify (i.e., anyone is eligible for their services). Most
clinics will see HIV-infected persons, regardless of sex or sexual orientation. Just over 50% of clinics offer their services to other high-risk groups (those with abnormal Pap, women with HPV, other immunosuppressed individuals) (Fig. 1).

**Screening/diagnosis**

Fifty-three percent of clinics will perform HRA in asymptomatic patients only if the anal cytology result is abnormal. Of these clinics, 74% use a cytology result of abnormal squamous cells of uncertain significance (ASC-US) or worse to trigger HRA, whereas 24% use low-grade squamous intraepithelial lesion (LSIL) or higher and 2% use a threshold of high-grade squamous intraepithelial lesion (HSIL). When performing HRA, 68% of respondents routinely do anal cytology concurrently while 32% of physicians routinely do HPV testing concurrently. Seventy-six percent routinely assess persons with external high-grade AIN, including Bowen’s disease, for the presence of internal AIN with HRA and guided biopsies, whereas only 28% of clinics routinely perform mapping or systematic four-quadrant biopsies to assess the extent of their external disease.

**Treatment**

Different therapeutic approaches were used for the treatment of internal and external AIN. The most commonly used treatment for internal disease is infrared coagulation (IRC) (61%) followed by imiquimod (54%) and bi/tri-chloroacetic acid (51%). External high-grade disease is most commonly treated with imiquimod (49%) followed by local fulguration strategies, including but not limited to IRC (Fig. 2A and B).

**Surveillance**

Respondents were asked to estimate the risk of recurrence of high-grade AIN after treatment in their clinics in various clinical scenarios. HIV-infected patients with a high burden of AIN were estimated to have the highest risk of recurrence of their high-grade disease (Fig. 3). Practitioners appear to rely on severity of AIN and to a lesser extent on immune status when planning the interval to the next HRA surveillance. In patients with a diagnosis of anal cancer in the last 2–5 years, most respondents recommended repeat surveillance within 1 year for immunocompetent patients and within 6 months for immunosuppressed patients. In all other scenarios, recommended time of repeat HRA surveillance appears to be independent of patients’ HIV status (Table 3).

**Personnel and training**

The majority of clinics have dedicated supporting services such as colorectal surgeons (69%), cytopathologists (66%), and histopathologists (66%). Most providers learned HRA by attending a formal course (82%) and/or by apprenticing with an experienced colleague (79%). Forty-four percent of providers train other personnel to do HRA.

**Payment/funding**

Private insurance, closely followed by public funds, are the two most common methods of payment for anal cancer screening tests in the United States, whereas in Canada and other countries public funds are almost exclusively used for payment (Fig. 4). In the United States, most clinics (83%) are funded by physician billings.
(i.e., insurance companies or health maintenance organizations [HMOs]), while the majority of clinics in other parts of the world receive funds from hospital budgets (65%) (Fig. 5).

**Discussion**

Our study is the first to describe current anal cancer screening practices globally. Just over half of the clinics that responded require that patients have an abnormal anal cytology result in order to proceed to HRA; the rest are performing HRA directly. Most clinics restrict their services to selected high-risk populations. Treatment of both high-grade and low-grade AIN is also offered in most clinics, however, less than two third of clinics offer HPV testing. Our respondents used ablative therapy most commonly for internal AIN and patient applied topical treatment for external AIN. However, there was considerable variation in the types of treatment offered for both internal and external AIN, suggesting a lack of consensus about the best treatment strategy among our respondents or differences in respondent expertise and access to the necessary equipment. Severity of AIN appears to be the principal factor in determining the interval respondents recommend between surveillance visits.

We found that almost half of clinics do not require an abnormal cytology result in order to proceed to HRA. To date, no long-term controlled trials have been performed to evaluate anal cancer screening; hence, practitioners often rely on the approaches used for cervical cancer screening [25]. In contrast to our findings, many guidelines [26, 27] for cervical cancer screening indicate that a screening test, usually a cervical Pap smear, should be done prior to colposcopy. Similarly, experts often recommend that anal cytology should be the first step in anal cancer screening; those patients with abnormal cytology results would then be further evaluated by HRA [7, 10, 24]. The data from several studies [11, 28–32] suggest that the sensitivity of anal cytology for the detection of biopsy-proven high-grade AIN in HIV-infected men is comparable to the sensitivity of cervical cytology for the detection of cervical high-grade disease. Despite these data, our respondents commonly reported direct use of HRA, rather than risk stratifying with cytology. This could partly be explained by a preference to do cytology at the time of HRA as a form of quality control for HRA findings, rather than as part of determining eligibility for HRA. While direct HRA is a resource intensive practice, interestingly, it was recently found to be the most cost-effective strategy for the detection of high-grade AIN in HIV-infected MSM [33]. The optimal approach to screening for anal cancer is not known; well-controlled prospective studies would help to guide clinical practice.

We found relatively low rates of HPV testing in our sample. MSM and HIV-infected individuals have high rates of anal cancer [2] and not surprisingly, the prevalence of HPV infection is also especially high in these
groups (86–98%) [11, 13–17]. As a result, anal HPV testing is not likely to be useful for risk stratification in these high-risk populations, as it is for cervical cancer screening in HIV-negative women where HPV infection is less common [34].

High-grade AIN is difficult to treat—recurrence is common, especially in immunocompromised populations where there is a higher likelihood of HPV persistence. According to our survey, IRC is most frequently used in clinical practice, particularly for the treatment of internal AIN. Goldstone et al. [35, 36] have performed retrospective reviews of the use of IRC for treating anal high-grade squamous AIN. Although recurrence was high after the first IRC, repeated treatment led to resolution of high-grade AIN, with a 72% probability of cure in retreated lesions in HIV-infected MSM. They report that IRC is a safe and effective procedure for treatment in both HIV-infected MSM and HIV-negative patients; this was further confirmed in a prospective pilot study by Stier et al. [37]. The second most common treatment used by our respondents is imiquimod. Several uncontrolled studies have found that imiquimod is a safe, effective, and well-tolerated treatment option for AIN in HIV-infected patients, with response rates ranging from 46% to 74% [38–40]. In contrast, a more recent study [41] showed electrocautery to be more effective and tolerable than topical imiquimod or 5-fluorouracil as a treatment for AIN in HIV-infected MSM, 57% of whom had high-grade disease. Despite these encouraging data, little is known about the long-term response rates. Larger studies with

---

**Figure 2.** Type of treatments offered in clinics/programs for internal (A) and external (B) anal intraepithelial neoplasia (AIN), reported as the proportion of clinics offering each treatment. IRC, infrared coagulation; LA or GA, local or general anesthesia; LE, local excision; LF, local ablation/fulguration; OR, operating room; TCA or BCA, trichloroacetic acid or bichloroacetic acid; WE, wide excision.
long-term follow-up are necessary to determine the most effective and most durable treatment options.

External high-grade AIN, including perianal Bowen’s disease, poses its own challenges. It is prone to local recurrence and treatment remains controversial [42, 43]. According to the literature, surgical excision appears to be the therapy of choice for Bowen’s disease [44–48]. In a survey of American colorectal surgeons, Cleary et al. [46] found that most surgeons advocate wide local excision for macroscopic small (96%) and large (87%) lesions, while favoring a more conservative option (i.e., observation alone) (74%) for patients with microscopic disease. In this study, however, respondents to our survey indicated that they used imiquimod more commonly than wide excision to treat Bowen’s disease. The reasons for this discrepancy between current clinical practice and the literature are unclear and may include perceived severity of the disease, the specialty of the treating physician or the preferences of their surgical colleagues. The literature supporting surgical remedies is relatively old; and, as also reported for high-grade vulvar intraepithelial neoplasia (VIN) [49, 50], there are recent case reports that support the use of imiquimod for Bowen’s disease [42, 51]. However, there have been no comparative effectiveness studies of different treatments for Bowen’s disease [42, 46].

The optimal surveillance protocol for persons with AIN is unknown. When recommending an interval to repeat surveillance, the majority of respondents in our study relied on the severity of the AIN and to a lesser extent, on immune status. Recommendations reported by our respondents appear to be consistent with an algorithm proposed by Abbasakoor and Boulos [52], which recommends a clinical review every 12 months in HIV-negative patients with low-grade AIN and every 4–6 months in HIV-infected or patients with high-grade AIN. Palefsky [53] recommends a slightly more aggressive schedule—clinical and cytological screening every 12 months in HIV-infected patients, every 6 months for those with low-grade AIN and every 3 months in patients with high-grade AIN. Cost-effectiveness studies by Goldie et al. [54, 55] recommend screening HIV-infected MSM annually and biennial screening of HIV-negative MSM. These recommendations, however, are based on limited evidence

**Figure 3.** Respondents’ estimations of the risk of posttreatment recurrence of high-grade dysplasia stratified by baseline risk. Estimated risk of recurrence: [0–20%], [21–40%], [41–60%], [61–80%], [81–100%].

**Table 3.** Interval recommended by 50% or more respondents for repeat HRA surveillance in (A) immunocompetent and (B) immunosuppressed patients stratified by baseline findings.

| Scenario | (A) Immunocompetent patients | (B) Immunosuppressed patients |
|----------|-------------------------------|-------------------------------|
| Negative anal Pap smear, negative HPV, negative high-resolution anoscopy | Within 2 years | |
| Low-grade dysplasia on anal pap smear, negative high-resolution anoscopy | Within 1 year | |
| High-grade dysplasia on anal pap smear, negative high-resolution anoscopy | Within 6 months | |
| Histologic low-grade dysplasia | Within 1 year | |
| Histologic high-grade dysplasia | Within 6 months | |
| Diagnosis of anal cancer in last 2 years | Within 6 months | |
| Diagnosis of anal cancer >2 years but <5 years ago | Within 1 year | Within 6 months |
| Diagnosis of anal cancer >5 years ago | Within 1 year | |

HRA, high-resolution anoscopy; HPV, human papillomavirus.
**Figure 4.** Methods of payment for various anal cancer screening tests, reported by number of clinics. Blue, publicly funded health coverage; green, private insurance; purple, patients; red, others. *More than one funding source may be reported.*

**Figure 5.** Funding source for clinic/program, reported by proportion of clinics. *More than one funding source may be reported. Blue, USA; green, others.*
about the long-term durability of treatment and the natural history of high-grade AIN, especially in HIV-infected persons on antiretrovirals. Therefore, studies to determine the most appropriate surveillance protocol are required.

Despite the relatively large number of clinicians who responded, our sample may still not be entirely representative. Efforts were made to be as inclusive as possible when identifying potential respondents by capitalizing on all existing resources available to us, including a literature review to identify persons who had published in the field. As a result, our response rate appears low, but this likely reflects the fact that our recruitment strategy included a high proportion of persons who do not perform HRA.

To our knowledge, the ASCCP is the only organization that provides formal training in HRA in the world. Abbreviated introductory courses in HRA have also been sponsored by the American Society of Colon and Rectal Surgeons (ASCRS) and the American College of Surgeons (ACS) via the ASCCP, but these organizations were not surveyed. Even so, our recruitment strategy should have identified most clinicians practicing in this field. However, we may have missed some clinicians, such as those who are trained by colleagues, for example, and not through a formal course. Nonetheless, we have responses from a large number of anal cancer screening clinics from around the world thus providing an arguably global perspective on the practice of anal cancer screening.

We have demonstrated considerable variation in anal cancer screening practice; there appears to be no universal consensus on optimal strategies for anal cancer screening, treatment, and follow-up. In large part, this is due to the lack of prospective controlled studies or well-designed observational studies. The incidence of anal cancer worldwide continues to increase likely in part because progression to invasive anal cancer from AIN is slow and HIV-infected individuals are now living longer. Hence, there is a need for rigorous studies to identify the most effective screening and treatment strategies in populations at high risk for anal cancer such as HIV-infected MSM. In the interim, the variation in practice that we have demonstrated is concerning and suggests the need for a formal consensus process whereby screening for, diagnosis and treatment of AIN is standardized using best available evidence and expert opinion.

**Conflict of Interest**

None declared.

**References**

1. Tinmouth, J., L. Paszat, and L. Rabeneck. 2006. Anal cancer in Ontario, 1971-2002: the relationship to socioeconomic status, sex and the HIV epidemic. Am. J. Gastroenterol. 101:S419.
2. D’Souza, G., D. J. Wiley, X. Li, J. S. Chmiel, J. B. Margolick, R. D. Cranston, et al. 2008. Incidence and epidemiology of anal cancer in the multicenter AIDS cohort study. J. Acquir. Immune Defic. Syndr. 48:491–499.
3. Shiels, M. S., R. M. Pfeiffer, A. K. Chaturvedi, A. R. Kreimer, and E. A. Engels. 2012. Impact of the HIV epidemic on the incidence rates of anal cancer in the United States. J. Natl. Cancer Inst. 104:1591–1598.
4. Cook, M. B., S. M. Dawsey, N. D. Freedman, P. D. Inskip, S. M. Wichner, S. M. Quraishi, et al. 2009. Sex disparities in cancer incidence by period and age. Cancer Epidemiol. Biomarkers Prev. 18:1174–1182.
5. Diamond, C., T. H. Taylor, T. Aboumrad, D. Bringman, and H. Anton-Culver. 2005. Increased incidence of squamous cell anal cancer among men with AIDS in the era of highly active antiretroviral therapy. Sex. Transm. Dis. 32:314–320.
6. Patel, P., D. L. Hanson, P. S. Sullivan, R. M. Novak, A. C. Moorman, T. C. Tong, et al. 2008. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann. Intern. Med. 148:728–736.
7. Chiao, E. Y., T. P. Giordano, J. M. Palefsky, S. Tying, and H. El Serag. 2006. Screening HIV-infected individuals for anal cancer precursor lesions: a systematic review. Clin. Infect. Dis. 43:223–233.
8. Silverberg, M. J., B. Lau, A. C. Justice, E. Engels, M. J. Gill, J. J. Goedert, et al. 2012. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin. Infect. Dis. 54:1026–1034.
9. Machalek, D. A., M. Poynten, F. Jin, C. K. Fairley, A. Farnsworth, S. M. Garland, et al. 2012. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol. 13:487–500.
10. Palefsky, J. M. 2009. Anal cancer prevention in HIV-positive men and women. Curr. Opin. Oncol. 21:438–438.
11. Salit, I. E., A. Lytwyn, J. Raboud, M. Sano, S. Chong, C. Diong, et al. 2010. The role of cytology (Pap tests) and human papillomavirus testing in anal cancer screening. AIDS 24:1307–1313.
12. Coutlee, F., A. de Pokomandy, and E. L. Franco. 2012. Epidemiology, natural history and risk factors for anal intraepithelial neoplasia. Sex. Health 9:547–555.
13. de Pokomandy, A., D. Rouleau, G. Ghattas, S. Vézina, P. Coté, J. Macleod, et al. 2009. Prevalence, clearance, and incidence of anal human papillomavirus infection in HIV-infected men: the HIPVIRG cohort study. J. Infect. Dis. 199:965–973.
14. Kreuter, A., N. H. Brockmeyer, B. Hochdurfer, S. J. Weissenborn, M. Stucker, J. Swoboda, et al. 2005. Clinical spectrum and virologic characteristics of anal
intrarepithelial neoplasia in HIV infection. J. Am. Acad. Dermatol. 52:603–608.
15. Palefsky, J. M., E. A. Holly, M. L. Ralston, and N. Jay. 1998. Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men. J. Infect. Dis. 177:361–367.
16. Palefsky, J. M., E. A. Holly, J. T. Efirdc, M. Da Costa, N. Jay, J. M. Berry, et al. 2005. Anal intrarepithelial neoplasia in the highly active antiretroviral therapy era among HIV-positive men who have sex with men. AIDS 19:1407–1414.
17. Critchlow, C. W., S. E. Hawes, J. M. Kuypers, G. M. Goldbaum, K. K. Holmes, C. M. Surawicz, et al. 1998. Effect of HIV infection on the natural history of anal human papillomavirus infection. AIDS 12:1177–1184.
18. Scholefield, J. H., M. T. Castle, and N. F. S. Watson. 2005. Malignant transformation of high-grade anal intrarepithelial neoplasia. Br. J. Surg. 92:1133–1136.
19. Watson, A. J. M., B. B. Smith, M. R. Whitehead, P. H. Sykes, and F. A. Frizelle. 2006. Malignant progression of anal intra-epithelial neoplasia. ANZ J. Surg. 76:715–717.
20. Kreuter, A., A. Potthoff, N. H. Brockmeyer, T. Gambichler, J. Swoboda, M. Stücker, et al. 2010. Anal carcinoma in human immunodeficiency virus-positive men: results of a prospective study from Germany. Br. J. Dermatol. 162:1269–1277.
21. Frisch, M., C. Fenger, A. J. C. van den Brule, P. Sørensen, C. J. L. M. Meijer, J. M. M. Walboomers, et al. 1999. Variants of squamous cell carcinoma of the anal canal and perianal skin and their relation to human papillomaviruses. Cancer Res. 59:753–757.
22. Daling, J. R., M. M. Madeleine, L. G. Johnson, S. M. Schwartz, K. A. Shera, M. A. Wurscher, et al. 2004. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 101:270–280.
23. Parkin DM, B. F. 2006. Chapter 2: the burden of HPV-related cancers. Vaccine 24(Suppl. 3):S11–S25.
24. Tinmouth, J., J. Raboud, M. Ali, L. Malloch, D. Su, M. Sano, et al. 2011. The psychological impact of being screened for anal cancer in HIV-infected men who have sex with men. Dis. Colon Rectum 54:359–359.
25. Sigel, K., R. Dubrow, M. Silverberg, K. Crothers, S. Braithwaite, and A. Justice. 2011. Cancer screening in patients infected with HIV. Curr. HIV/AIDS Rep. 8:142–152.
26. USPSTF. 2012. Screening for Cervical Cancer: U.S. Preventive Services Task Force Recommendation Statement: AHRQ Publication No. 11-05156-ES-F2, March 2012. Available at http://www.uspreventiveservicestaskforce.org/uspstf11/cervcancer/cervcancers.htm (accessed 29 October 2012).
27. Canadian Task Force on Preventive Health Care. 2013. Recommendations on screening for cervical cancer. CMAJ 185:35–45.
28. Palefsky, J. M., E. A. Holly, C. J. Hogeboom, J. M. Berry, N. Jay, and T. M. Darragh. 1997. Anal cytology as a screening tool for anal squamous intraepithelial lesions. J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol. 14:415–422.
29. Lee, A., T. Young, D. Hanks, R. Ung, and J. Stansell. 2004. The evaluation of anal dysplasia with anal cytology (Pap) followed by high resolution anoscopy (HRA) and biopsy in HIV-infected men. Int. Conf AIDS. 15 (abstract).
30. Mathews, W. C., A. Sitapati, J. Caperna, R. E. Barber, A. Tugend, and U. Go. 2004. Measurement characteristics of anal cytology, histopathology, and high-resolution anoscopic visual impression in an anal dysplasia screening program. J. Acquir. Immune Defic. Syndr. 37:1610–1615.
31. Panther, L. A., K. Wagner, J. Proper, D. K. Fugelso, P. A. Chatis, W. Weeden, et al. 2004. High resolution anoscopy findings for men who have sex with men: inaccuracy of anal cytology as a predictor of histologic high-grade anal intrarepithelial neoplasia and the impact of HIV serostatus. Clin. Infect. Dis. 38:1490–1492.
32. Fox, P. A., J. E. Sest, J. Stebbing, N. Francis, S. E. Barton, S. Strauss, et al. 2005. The value of anal cytology and human papillomavirus typing in the detection of anal intrarepithelial neoplasia: a review of cases from an anoscopy clinic. Sex. Transm. Infect. 81:142–146.
33. Lam, J. M. C., J. S. Hoch, J. Tinmouth, M. Sano, J. Raboud, and I. E. Salit. 2011. Cost-effectiveness of screening for anal precancers in HIV-negative men. AIDS 25:635–642.
34. Saslow, D., D. Solomon, H. W. Lawson, M. Killackey, S. L. Kulasingam, J. M. Cain, et al. 2012. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J. Low. Genit. Tract Dis. 16:175–204.
35. Goldstone, S. E., A. Z. Kawalek, and J. W. Huyett. 2005. Infrared coagulator: a useful tool for treating anal squamous intraepithelial lesions. Dis. Colon Rectum 48:1042–1054.
36. Goldstone, S. J. Hundert, and J. Huyett. 2007. Infrared coagulator ablation of high-grade anal squamous intraepithelial lesions in HIV-negative males who have sex with males. Dis. Colon Rectum 50:565–575.
37. Stier, E. A., S. E. Goldstone, J. M. Berry, L. A. Panther, N. Jay, S. E. Krown, et al. 2008. Infrared coagulator treatment of high-grade anal dysplasia in HIV-infected individuals: an aids malignancy consortium pilot study. J. Acquir. Immune Defic. Syndr. 47:56–61.
38. Wieland, U., N. H. Brockmeyer, S. J. Weissabenorn, B. Hochdorfer, M. Stucke, J. Swoboda, et al. 2006. Imiquimod treatment of anal intraepithelial neoplasia in HIV-positive men. Arch. Dermatol. 142:1438–1444.
39. Sanclemente, G., S. Herrera, S. K. Tyring, P. L. Rady, J. J. Zuleta, L. A. Correa, et al. 2007. Human
papillomavirus (HPV) viral load and HPV type in the clinical outcome of HIV-positive patients treated with imiquimod for anogenital warts and anal intraepithelial neoplasia. J. Eur. Acad. Dermatol. Venereol. 21:1054–1060.

40. Kreuter, A., A. Potthoff, N. H. Brockmeyer, T. Gambichler, M. Stucker, P. Altmeier, et al. 2008. Imiquimod leads to a decrease of human papillomavirus DNA and to a sustained clearance of anal intraepithelial neoplasia in HIV-infected men. J. Invest. Dermatol. 128:2078–2083.

41. Richel, O., H. de Vries, C. van Noesel, M. Dijkgraaf, and J. Prins. 2012. Treatment of anal intraepithelial neoplasia in HIV positive MSM: a triple arm randomised clinical trial of imiquimod, topical 5-fluorouracil and electrocautery. Abstract R1002, paper 135LB. 19th Conference on Retroviruses and Opportunistic Infections, Seattle.

42. van Egmond, S., C. Hoedemaker, and R. Sinclair. 2007. Successful treatment of perianal Bowen’s disease with imiquimod. Int. J. Dermatol. 46:318–319.

43. Cleary, R. K., J. D. Schaldenbrand, J. J. Fowler, J. M. Schuler, and R. M. Lampman. 1999. Perianal Bowen’s disease and anal intraepithelial neoplasia: review of the literature. Dis. Colon Rectum 42:945–951.

44. Sarmiento, J. M., B. G. Wolff, L. J. Burgart, F. A. Frizelle, and D. M. Ilstrup. 1997. Perianal Bowen’s disease: associated tumors, human papillomavirus, surgery, and other controversies. Dis. Colon Rectum 40:912–918.

45. Marchesa, P., V. W. Fazio, S. Oliart, J. R. Goldblum, and I. C. Lavery. 1997. Perianal Bowen’s disease: a clinicopathologic study of 47 patients. Dis. Colon Rectum 40:1286–1293.

46. Cleary, R. K., J. D. Schaldenbrand, J. J. Fowler, J. M. Schuler, and R. M. Lampman. 2000. Treatment options for perianal Bowen’s disease: survey of American Society of Colon and Rectal Surgeons Members. Am. Surg. 66:686–688.

47. Cox, N. H., D. J. Eedy, and C. A. Morton. 1999. Guidelines for management of Bowen’s disease. British Association of Dermatologists. Br. J. Dermatol. 141:633–641.

48. Cox, N. H., D. J. Eedy, and C. A. Morton. 2007. Therapy Guidelines and Audit Subcommittee BAoD. Guidelines for management of Bowen’s disease: 2006 update. Br. J. Dermatol. 156:11–21.

49. Mahto, M., M. Nathan, and C. O’Mahony. 2010. More than a decade on: review of the use of imiquimod in lower anogenital intraepithelial neoplasia. Int. J. STD AIDS 21:8–16.

50. Iavazzo, C., E. Pitsouni, S. Athanasiou, and M. E. Falagas. 2008. Imiquimod for treatment of vulvar and vaginal intraepithelial neoplasia. Int. J. Gynecol. Obstet. 101:3–10.

51. Gutzmer, R., M. Kaspari, M. Vogelbruch, P. Kiehl, A. Kapp, T. Werfel, et al. 2002. Successful treatment of anogenital Bowen’s disease with the immunomodulator imiquimod, and monitoring of therapy by DNA image cytometry. Br. J. Dermatol. 147:160–165.

52. Abbasakoor, F., and P. B. Boulos. 2005. Anal intraepithelial neoplasia. Br. J. Surg. 92:277–290.

53. Palefsky, J. M. 2000. Anal squamous intraepithelial lesions in human immunodeficiency virus-positive men and women. Semin. Oncol. 27:471–479.

54. Goldie, S., K. Kuntz, M. Weinstein, K. Freedberg, M. Welton, and J. M. Palefsky. 1999. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. JAMA 281:1822–1829.

55. Goldie, S. J., K. M. Kuntz, M. C. Weinstein, K. A. Freedberg, and J. M. Palefsky. 2000. Cost-effectiveness of screening for anal squamous intraepithelial lesions and anal cancer in human immunodeficiency virus-negative homosexual and bisexual men. Am. J. Med. 108:634–641.